September 27, 2019
Takeda Pharmaceutical said on September 26 that its inflammatory bowel disease treatment Entyvio (vedolizumab) demonstrated superiority to the TNFα monoclonal antibody Humira (adalimumab) in clinical remission in moderate to severe active ulcerative colitis patients in a head-on comparison study. In...read more